Kolon Life Science Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 26.73 million compared to KRW 27.26 million a year ago. Net loss was KRW 5,635.23 million compared to net income of KRW 5,044.72 million a year ago. Basic loss per share from continuing operations was KRW 508 compared to basic earnings per share from continuing operations of KRW 456 a year ago. Diluted loss per share from continuing operations was KRW 508 compared to diluted earnings per share from continuing operations of KRW 412 a year ago. Basic loss per share was KRW 493 compared to basic earnings per share of KRW 442 a year ago. Diluted earnings per share was KRW 13 compared to diluted loss per share of KRW 13 a year ago.
For the six months, sales was KRW 77.17 million compared to KRW 54.52 million a year ago. Net loss was KRW 10,295.25 million compared to net income of KRW 2,183.93 million a year ago. Basic loss per share from continuing operations was KRW 1,158 compared to basic earnings per share from continuing operations of KRW 233 a year ago. Diluted loss per share from continuing operations was KRW 1,158 compared to diluted earnings per share from continuing operations of KRW 211 a year ago. Basic loss per share was KRW 902 compared to basic earnings per share of KRW 191 a year ago. Diluted earnings per share was KRW 231 compared to diluted loss per share of KRW 38 a year ago.